Rheumatoid arthritis (RA)
PrCIMZIA® (certolizumab pegol) in combination with methotreaxate (MTX) is indicated for:
- reducing signs and symptoms, inducing major clinical response, and reducing the progression of joint damage as
assessed by X-ray, in adult patients with moderately to severely active rheumatoid arthritis (RA).
PrCIMZIA® may be used alone for reducing signs and symptoms in adult patients with moderately to severely active
rheumatoid arthritis (RA) who do not tolerate MTX.
